Genetic Screening Testing for Preventive Health Market is predicted to grow at a 11.8% CAGR during the forecast period for 2025-2034.
Analyzing a person's genetic composition to forecast their risk of contracting specific diseases or ailments in the future is known as genetic screening tests for preventative health. These tests are intended to detect genetic susceptibilities to several illnesses, including diabetes, cancer, heart disease, and other inherited conditions. Due to factors such as growing consumer interest in personalized treatment, the development of preventive healthcare policies, and technical improvements, the market for genetic screening tests in preventive health has been expanding quickly. From detecting particular gene mutations to determining a person's risk for chronic illnesses, genetic testing for preventative health may do it all. Through early lifestyle modifications or medical interventions, these tests assist people in taking proactive measures to manage their health and possibly lower their chance of acquiring illnesses. The market for genetic screening testing for preventive health encompasses carrier screening for inherited diseases and genetic testing for common and uncommon genetic abnormalities.
In addition, more people are realizing the advantages of early disease detection and management, which highlights the significance of preventative healthcare. Organizations, medical experts, and public health campaigns have emphasized the importance of genetic screening in identifying health problems before symptoms manifest, which has increased market demand.
Some Of The Major Key Players In The Genetic Screening Testing For Preventive Health Market
• Exact Science
• Labcorp Genetics Inc.
• Dante Labs US
• Myriad Genetics, Inc.
• Blueprint Genetics
• Ambry Genetics
• Revvity
• Laboratory Corporation of America Holdings
• BGI Group
• Genex Diagnostics Inc.
• Sonic Healthcare
• Fulgent Genetics
Market Segmentation:
The genetic screening testing for preventive health market is segmented based on test type, technology, application, and end-user. Based on test type, the market is segmented into carrier screening tests (expanded carrier screening, targeted carrier screening), non-invasive prenatal tests, preimplantation genetic testing, and newborn screening. By technology, the market is segmented into NGS, Microarray, PCR, FISH, and others. The market is segmented by application into oncology, cardiovascular diseases, reproductive health, neurodegenerative health, rare diseases, and others. The market is segmented by end-users into hospitals and diagnostic laboratories, dtc companies, genetic counselling services, and other end-users.
Based On The Test Type, The Non-Invasive Prenatal Test Segment Is Accounted As A Major Contributor To The Genetic Screening Testing For Preventive Health Market
The Non-Invasive Prenatal Test category is expected to hold a major global market share in 2024 driven by improvements in genetic testing methods, growing mother age, and growing awareness of early fetal health screening. Pregnant women and medical professionals are more likely to use NIPT since it provides a safer and more accurate substitute for more intrusive treatments like amniocentesis. Further driving market expansion is the growing accessibility of NIPT in hospitals, diagnostic facilities, and direct-to-consumer platforms. Furthermore, NIPT is becoming a more popular option for prenatal screening due to its accessibility, rising insurance coverage, decreasing test costs, and regulatory approvals.
PCR Segment To Witness Growth At A Rapid Rate
The Polymerase Chain Reaction (PCR) category's high sensitivity, specificity, and quick turnaround time for identifying genetic alterations and disease predispositions are driving its rise in the Genetic Screening Testing for Preventive Health Market. PCR is an essential technique for risk assessment, early illness identification, and individualized preventive healthcare measures because of its capacity to amplify minute DNA samples. The need for PCR-based genetic screening is being driven by the rising incidence of genetic illnesses as well as increased knowledge of preventative health measures. The accuracy and efficiency of PCR technology are being further improved by developments like digital PCR and real-time quantitative PCR (qPCR), which will increase their use in clinical and research contexts.
In The Region, The North American Genetic Screening Testing For Preventive Health Market Holds A Significant Revenue Share
The North American Genetic Screening Testing for Preventive Health market is expected to register the highest market share in revenue in the near future driven by advancements in technology, a robust healthcare system, and growing consumer awareness. The United States, in particular, is a prominent player because of its established healthcare system, extensive research on genetic testing, and increasing focus on tailored therapy. Additionally, the advent of direct-to-consumer genetic testing businesses like 23andMe has increased market penetration. In addition, Asia Pacific is projected to grow rapidly in the global Genetic Screening Testing for Preventive Health market fueled by growing healthcare infrastructure investment, economic growth, and healthcare awareness. China, Japan, India, and South Korea are among the nations that are becoming crucial genetic testing markets. Japan and South Korea are developing the standard for cutting-edge medical technology despite China and India having sizable populations with a wide range of genetic profiles.
Genetic Screening Testing For Preventive Health Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 11.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; Japan; South Korea; Southeast Asia |
|
Competitive Landscape |
Exact Science, Labcorp Genetics Inc., Dante Labs US, Myriad Genetics, Inc., Blueprint Genetics, Ambry Genetics, Revvity, Laboratory Corporation of America Holdings, BGI Group, Genex Diagnostics Inc., Sonic Healthcare, and Fulgent Genetics. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
